EUropean Pharmacogenetics of AntiCoagulant Therapy - Warfarin

PHASE4CompletedINTERVENTIONAL
Enrollment

455

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

October 31, 2013

Study Completion Date

October 31, 2013

Conditions
Venous ThromboembolismAtrial Fibrillation
Interventions
OTHER

Genotype-guided dosing algorithm

Loading and monitoring dose according to genotype-guided dosing algorithm

OTHER

Standard care

Standard care

Trial Locations (3)

Unknown

Uppsala University, Uppsala

University of Liverpool, Liverpool

University of Newcastle, Newcastle

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Utrecht University

OTHER

collaborator

Leiden University Medical Center

OTHER

collaborator

Erasmus Medical Center

OTHER

collaborator

University of Ulm

OTHER

collaborator

Newcastle University

OTHER

collaborator

University of Liverpool

OTHER

collaborator

LGC Limited

INDUSTRY

collaborator

Uppsala University

OTHER

collaborator

Democritus University of Thrace

OTHER

collaborator

Elisabethinen Hospital

OTHER

lead

Utrecht Institute for Pharmaceutical Sciences

OTHER

NCT01119300 - EUropean Pharmacogenetics of AntiCoagulant Therapy - Warfarin | Biotech Hunter | Biotech Hunter